GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Other Cash Receipts from Operating Activities

Hyloris Pharmaceuticals (XBRU:HYL) Other Cash Receipts from Operating Activities


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Other Cash Receipts from Operating Activities?

Other Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Other Cash Receipts from Operating Activities
Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.